Department of Neurology, Mayo Clinic and Foundation, Rochester, Minnesota , USA. This Site. Google Scholar. J D Schmelzer ; J D Schmelzer. P J Zollman ; P J Zollman. K K Nickander ; K K Nickander. H J Tritschler ; H J Tritschler. Diabetes ;48 10 — Get Permissions.

toolbar search Search Dropdown Menu. toolbar search search input Search input auto suggest. This content is only available via PDF. View Metrics. Email alerts Article Activity Alert. Online Ahead of Print Alert. Latest Issue Alert.

Most Read Most Cited MRI Metrics of Cerebral Endothelial Cell—Derived Exosomes for the Treatment of Cognitive Dysfunction Induced in Aging Rats Subjected to Type 2 Diabetes. Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel.

Genetic Influences of Adiponectin on Insulin Resistance, Type 2 Diabetes, and Cardiovascular Disease. Online ISSN X Print ISSN Books ShopDiabetes. org ADA Professional Books Clinical Compendia Clinical Compendia Home News Latest News DiabetesPro SmartBrief. Resources ADA Professional Membership ADA Member Directory Diabetes.

X Twitter Facebook LinkedIn. This Feature Is Available To Subscribers Only Sign In or Create an Account. Close Modal.

This site uses cookies. In AD, ALA in association with n-acetylcysteine has shown to have a protective effect upon oxidative stress in fibroblasts decreasing caspase proteins which were responsible for apoptotic processes in patients with AD [ 14 ]. In a triple transgenic animal model of AD, ALA was able to improve neurons plasticity and improve many pathways of insulin signaling in the brain similar to the action described with metformin [ 77 , 78 ].

One study was conducted with nine patients followed by 12 months [ 79 ] and the other with 43 patients followed by 24 months [ 68 ], both showing a slowing in the disease progression. Meanwhile, when ALA was associated with exercise training in animal model an increase in some antioxidant enzymes were observed [ 81 ].

The increasing prevalence of obesity worldwide is an important epidemiological issue because it is occurring in parallel with the increase in the prevalence of DM and cardiovascular disease CVD. Moreover, it is well known that both conditions are associated with insulin resistance, an increased plasmatic level of free fatty acids, of pro-inflammatory cytokines such as tumor necrosis factor alfa TNF-α , interleukin 6 IL-6 and decreased levels of adiponectin which is considered to be a protective cytokine [ 65 , 82 , 83 ].

The above-mentioned mechanisms seem to be related to oxidative stress and activation of NfKB [ 84 ]. ALA has many actions that may result in weight loss such as activation of AMPK in peripheral and brain tissue [ 59 ], inhibition of NfKB [ 44 ] and adipocyte differentiation [ 65 ].

Animal studies showed that rats fed with a high fat diet with ALA supplementation had less weight gain and better plasmatic lipid profile than the control group [ 65 ].

Some of these effects, such as the increase in HDL-cholesterol and the decrease in LDL-cholesterol levels were dose dependent. Some studies suggest that the ability of ALA supplementation in preventing insulin resistance might be related in part to the stimulation of AMPK and adiponectin in white adipose tissue [ 82 ] and attenuation of monocyte chemokine protein 1 MCP-1 and TNF-α [ 71 ].

The authors suggested that ALA may modulate visceral adipose inflammation. Data from human studies have shown conflicting results related to lipid metabolism [ 8 , 85 — 88 ]. However, in obese glucose intolerant subjects ALA has only shown an increase in LDL-oxidation in comparison to subjects who completed 12 weeks of ALA used associated with exercise [ 8 ].

Another study did not show any advantage of ALA supplementation for two weeks over lipid-induced insulin resistance in obese or overweight subjects [ 85 ]. However, an intravenous treatment with mg of ALA for two weeks in obese patients with glucose intolerance resulted in improvement of insulin resistance, decreased levels of free fatty acids, LDL-cholesterol as well oxidized LDL, TNF α and IL-6 [ 86 ].

The weight loss was greater in patients taking antihistaminic antipsychotic agents, mainly clozapine, olanzapine or quetiapine [ 88 ]. Further studies are necessary to address the clinical use of ALA as anti-obesity drug with more complete data about dietary habits including the ingestion of fruits and vegetables which are the main source of antioxidants in a regular diet.

Non-alcoholic fatty liver disease NAFLD is considered the most prevalent liver disease worldwide. NAFLD is frequently associated with metabolic syndrome, obesity, DM and dyslipidemia [ 90 ].

Currently, mitochondria dysfunction, oxidative stress and inflammation play a key role in the pathogenesis of NAFLD and NASH [ 55 ]. Some animal studies have brought to light the possible mechanisms involved in the action of ALA in NAFLD and NASH in the last years [ 92 , 93 ].

In one study, the use of ALA was followed by improvement in serum levels of insulin, free fatty acids, glucose, IL-6, triglycerides and markers of inflammation and of innate immune activation Toll-like receptor 4, TLR4 in liver biopsy [ 93 ].

Two other studies using animals fed with a high fat diet showed that ALA induced an increase in uncoupling protein 2 which inhibits electron transport chain resulting in decreased ATP and lipid synthesis [ 92 ].

Moreover this action on mitochondria efficiency seems to be related to an increased action of the sirtuin proteins [ 94 ].

These proteins have many actions in several intracellular pathways associated with antioxidant defense [ 95 , 96 ]. Burning mouth syndrome BMS is a chronic disease characterized by pain, burning and itching of the oral cavity without association to any systemic disease.

Sometimes xerostomia and dysgeusia could be present [ 97 ]. BMS is more prevalent in women in the menopause period. The etiology is probably multifatorial including psychiatric diseases and hypothyroidism [ 99 ]. ALA was used during two months in patients with BMS in a dose of mg daily but with conflicting results [ 98 — ].

The main cause of mortality in non diabetic as well as in diabetic subjects worldwide is CVD [ ]. CVD is multifactorial being the oxidative stress and a pro-inflammatory state considered to be the most important mechanisms involved in the large spectrum of CVD [ ].

In this setting, ALA which has antioxidant as well anti-inflammatory actions has been used in several studies, both animal [ 8 — 10 , 68 — 70 ] and human [ 9 , ] addressing different aspects of CVD. For instance, the acute use of ALA in a mg dose, associated with 1, mg of vitamin C and IU of Vitamin E was able to ameliorate markers of oxidative stress and endothelial dysfunction evaluated by flow-mediated vasodilation FMD of the brachial artery in the elderly [ 7 ].

The effects of ALA upon endothelial function and markers of oxidative stress were age dependent and it was not observed in young subjects. In contrast, a review of many clinical trials using chronic antioxidant therapy was not able to demonstrate benefits on CVD [ ].

In animal models, those fed with a high cholesterol diet, the use of ALA for 12 weeks reduced oxidative stress and weight and improved vascular reactivity [ 10 ].

Moreover, a reduction in the wall volume of abdominal aorta with slowing rate of the plaque progression and a reduction of the expression of adhesion molecules in thoracic aorta were also observed.

One important finding in this study was the demonstration that ALA decreased the activation of NfKB which regulates the expression of pro-inflammatory genes as well adhesion molecules [ 10 ]. The effects and mechanisms of ALA on myocardial infarct size and diabetic cardiomyopathy which is defined as a ventricular dysfunction in diabetic patients without any other cause, were also evaluated in animal studies [ 66 , 67 ].

Cardiac fibrosis which is the main feature of cardiomyopathy, was investigated in animal with streptozotocin STZ DM-induced [ 66 ]. In these animals the use of ALA had different actions such as improvement of cardiac function and cardiac fibrosis. Analyzing the left ventricular sections of these animals it was observed a better oxidative stress profile and a decreased expression of transforming growth factor β and smooth muscle actin, both associated with collagen production.

In animal models of ischemia-reperfusion it was demonstrated that ALA ameliorates cardiac dysfunction with a decrease in the infarct size, TNF-α, mieloperoxidase, markers of cell death lactate dehydrogenase and creatinine kinase , and upregulates gene expression of several antioxidant enzymes [ 67 ].

No effects with lower or higher doses were observed [ 67 ]. In animal studies of glucocorticoid-induced hypertension, the use of ALA prevented only dexamethasone induced-hypertension [ 65 ]. In human studies the use of ALA as a hypotensive agent presented conflicting results showing improvement or no effect [ 52 , ].

Moreover it was also demonstrated that both drugs had a synergistic effect upon markers of endothelial dysfunction, inflammation and oxidative stress. It is important to emphasize that this study was not designed to evaluate blood pressure and the dose used of ALA was lower than the doses that are usually employed.

Oxidative stress plays an important role in tumorigenesis [ ]. ALA has been used as an anticancer agent mainly in experimental studies of different tumorigenesis cells type with promising results [ 16 , — ].

So far the exact molecular mechanisms involved in this action are unknown. Besides its antioxidant acitivity, another possibility could be its relation to the capacity of inducing cellular apoptosis as recently demonstrated in lung cells [ ].

This effects may result from activation of caspases proteins induced by endoplasmic reticulum stress [ ]. Another hypothesis is associated with the metabolism of cancer cells which convert preferentially glucose to lactate, a mechanism known as the Warburg effect [ ].

ALA is the cofactor of pyruvate deydrogenase which converts pyruvate to acetil CoA resulting in a decrease in the formation of lactate [ ]. The net effect of this action is the inhibition of glycolysis.

Additionally, an inhibition of mTOR target of rapamycina , a signaling pathway responsible for cell growth and related to insulin receptor phosphorylation- PI3K-AKT activation, has been demonstrated in assays using insulinoma cells [ 57 ].

This action resulted in an inhibition of insulin secretion and of beta cells growth [ 57 ]. In addition, in this study it was also showed a direct binding site of ALA to insulin receptor [ ].

It is possible to speculate that ALA can act in alternative routes resulting in different effects. The few studies in humans are case reports [ ]. In these studies ALA was used associated with other antioxidant agents [ ] or with other anticancer drugs [ ].

ALA has been used in other clinical conditions such as glaucoma [ 72 ] and osteoporosis [ , ]. Both conditions are associated with an imbalance in the redox state. In a mouse model of glaucoma the increase in intraocular pressure was correlated to increased levels of lipid peroxidation and of oxidative stress-related genes expression in retina.

Moreover, in these animals the addition of ALA to the diet enhanced antioxidant defenses, prevented retinal ganglion cell losses without significant intraocular pressure changes. In a rat model of estrogen deficiency induced by ovariectomy the use of ALA increased bone mineral density BMD and decreased inflammatory markers such as TNF- α and IL Besides these effects, the use of ALA also decreased the levels of osteopontin, a protein related to bone resorption [ ].

In a model of low BMD induced by high-fat diet, which is a potent inducer of oxidative stress, the ALA supplementation resulted in an increase of the levels of expression of genes related to antioxidant enzymes, BMD, and biomarkers of bone formation, such as osteocalcin, and a down regulation of genes related to bone resorption activity, like osteoprotegerin, in femur biopsy.

These studies indicated a possible action of ALA upon maintenance of bone balance. The World Health Organization WHO , estimated that by there will be million people with DM in the world.

DM carries a great risk of morbidity and mortality due to the microvascular and macrovascular complications that can lead to a lower quality of life and life expectancy [ ].

Currently, these complications can be postponed by achieving adequate glycemic control, as demonstrated by the Diabetes Control and Complications Trial, the Epidemiology of Diabetes Interventions and Complications and UKPDS [ — ].

However in routine clinical practice good glycemic control is very difficult to be achieved [ , ]. The aforementioned diabetes-related complications lead to a significant burden to the individual and to the society as a whole [ , ].

The mechanisms underlying the development of DM related- chronic complications either micro or macrovascular are associated to glycemic control [ 90 , — ]. However, many other factors may contribute or have a direct relationship with these complications, such as oxidative stress [ ], markers of insulin resistance [ ], markers of low-grade inflammation [ ], dyslipidemia [ ], hypertension [ , ] and obesity [ ].

Indeed, DM-related complications may be considered multifactorial as DM itself [ ]. In this context, oxidative stress- related hyperglycemia is considered to be more and more important in the development of DM as well in the development of its related complications [ 85 , ].

This duet, oxidative stress- related hyperglycemia may induce modifications in signaling pathways responsible for several intracellular processes [ ].

Some of these processes are related to inhibition of insulin signaling pathway resulting in insulin resistance [ ], reduced insulin gene expression and consequently reduced insulin secretion by beta cells [ ].

Moreover, currently there is compelling evidence linking this duet to epigenetic modifications resulting in activation of genetic transcription or repression, silencing the genetic transcription as recently described [ 45 ]. In this study it was shown an increasing expression of the subunit p65 of NfKB which resulted in increased transcription of vascular cell adhesion.

molecule-1 VCAM-1 and monocyte chemo attractant molecule-1 MCP-1 in human aortic endothelial cells under hyperglycemia medium [ 45 ]. MCP-1 and VCAM are both related to hyperglycemia-induced arterial pathology. Moreover, this reaction persisted after a long period of normoglycemia establishing the concept of metabolic memory at molecular level.

Recently it was demonstrated also a downregulation of LASY in diabetic animals [ 18 ]. In this study either treatment with medium with high glucose or TNF-α resulted in reduction of LASY mRNA [ 18 ]. Moreover, a knockout of LAISY showed an intracellular decrease in GSH, superoxide dismutase SOD and catalase and an increase in superoxide anion resulting in activation of NfKB, Adding ALA in the cellular medium an up-regulation of LAISY expression was observed [ 18 ].

Another important factor in the pathogenesis of diabetes-related complications is the formation of advanced glycation end-products AGEs which are derived from intracellular glucose auto-oxidation and non-enzymatic reactions between glucose and intracellular and extracellular proteins [ — ].

AGEs by different mechanisms may damage target cells located in retina, endothelium and glomeruli [ ]. AGE may also activate PKC which is a signal transduction pathway for regulating many vascular functions like blood flow, permeability, basement membrane thickening and the expression of nitric oxide synthase [ ].

Considering the pleiotropic actions of ALA or its reduced form, DHLA in many signaling pathways associated with the pathophysiologic process of DM development as well as the development of its above mentioned chronic-related complications, its use as a therapeutic agent sounds promising.

Although an improvement in HbA1c, weight and waist have been observed with ALA, omega 3 fatty acids gave the better results concerning weight loss and glycemic control [ ]. However, there was only a statistical significant difference only with the pooled group of ALA.

The reduction of HbA1c was ALA dose-dependent. Moreover, markers of oxidative stress such as lipid peroxidation and oxidative damage of DNA did not show any modification.

Data obtained in clinical studies using ALA in the treatment of diabetes-related complications are summarized in Table 2. ALA has been used to evaluate retinal mitochondria biogenesis in rats in a model of reinstitution of good control after six months of poor metabolic control [ ].

In animals without ALA supplementation and under poor glycemic control it was observed a dysregulation of retinal mitochondria biogenesis with a decreased expression of citrase synthase a marker of mitochondria functional integrity , a decreased number of mitochondria and an increased number of acellular capillaries a marker of diabetic retinopathy.

Moreover, in this study the supplementation of ALA in animals soon after induction of DM prevented most of the above-mentioned alterations [ ]. In another experimental study, the treatment with ALA in diabetic animals reduced the markers of oxidative stress, NfKB activation and vascular endothelial growth factor in diabetic retina [ ].

The effects of ALA in the development of diabetic nephropathy was investigated mainly in animal studies. In diabetic animal strepzotocin STZ -induced DM and apolipoprotein deficient fed high fat diet the protective effect of ALA supplementation was evaluated in three different time schedule : pre-STZ, simultaneously and pos-STZ.

No statistical difference was noted among the groups concerning hyperglycemia, although an attenuation of hyperglycemia was observed in the group pre-STZ. Analyzing the pooled group it was found a reduction in IL-6, urine albumin, urine isoprostane and an increase in erythrocyte GSH in the group under ALA supplementation.

The decreased gene expression of superoxide dismutase in diabetic animals was normalized with ALA. Two other animal studies showed interesting data [ , ]. One study showed that LASY-deficient animals present reduction in antioxidant defense.

Moreover, in this study it was also found an overproduction of superoxide in the proximal tubular cells which could be an important event for accelerating the development of diabetic nephropathy [ ].

Another study showed opposite action of ALA in animals with STZ-induced DM. In diabetic animals ALA decreased urinary albumin and markers of oxidative stress, but in non-diabetic animals pro-oxidant effects were observed with an increase in urinary albumin, creatinine and markers of oxidative stress [ ].

This effect may be at least partially explained by the high dose used in the experiment. So far, the few human studies which have been done had different objectives [ — ]. Moreover this reduction was independent of the level of HbA1c and urine albumin [ ].

The protective effect of ALA on the development of contrast-induced nephropathy CIN was evaluated in 68 patients with DM undergoing coronary angiography. The patients received mg of TA prior to the procedure or no treatment control group.

The effect of ALA upon asymmetric dimetihylarginine ADMA which is an inhibitor of nitric oxid synthase, was investigated in a randomized, control study for 12 week in 50 diabetic patients undergoing hemodyalisis.

A decrease in the level of trombomodulin and no changes in the urinary albumin were observed in the treatment group [ ]. A randomized, controlled, double blind, parallel study with 30 patients with T2D evaluated glycemic control and endothelial responses to intravenous acetylcholine endothelium dependent and nitrate endothelium independent in order to evaluate the forearm blood flow before and after the use of mg of ALA intravenously for three weeks [ ].

A decrease in HbA1c, total cholesterol and triglycerides levels were observed in both groups. However only the patients ALA treated showed an improvement in the endothelium dependent vasodilation. ALA or placebo did not influence endothelium independent vasodilation [ ]. An experimental study in vitro and in vivo has demonstrated a possible benefit of topical application of ALA alone or in combination with other anti-oxidant agents for diabetic wound healing [ ].

In this study the expression of RAGE was attenuated in skin wound in diabetic animals when ALA was used in combination with other anti-oxidants agents for one week. Moreover, the use of ALA in combination with other anti-oxidants agents accelerated the skin wound healing with increased expression of vascular endothelial growth factor VEGF in the wound area.

Cardiovascular autonomic neuropathy was evaluated in two human studies. One, randomized, double blind, placebo controlled multicenter study DEKAN was conducted in patients with T2D with cardiovascular autonomic neuropathy CAN using mg of ALA daily for 16 weeks [ ]. Autonomic symptoms and heart rate variability were evaluated before and after the intervention.

The intervention with ALA resulted in improvement of some parameters of heart rate variability analysis: root mean square successive difference and power spectrum in low frequency band. No difference was observed in overall symptoms. Another study, a prospective, randomized, double blind, placebo controlled study was performed in 44 patients with T1D presenting any diabetes-related chronic complication mild non-proliferative retinopathy or microalbuminuria and the presence of cardiac autonomic neuropathy CAN defined by an alteration of positron emission tomography PET with normal autonomic reflex testing [ ].

In this study no improvement was found in all parameters of autonomic function analysis as well as in urinary levels of isoprostanes, a marker of oxidative stress.

Meanwhile a detrimental effect in some regions of left ventricle was observed in PET analysis [ ]. So far, the majority of clinical studies using ALA therapeutically were conducted in order to evaluate its action on diabetic neuropathy.

The main benefit of ALA was an improvement of symptoms and in distal motor never latencies. It is beyond the scope of this review to analyze each of these studies but they did not have a definite conclusion about the effects of ALA upon diabetic neuropathy. However they have given key information about how to perform other clinical trials better designed to in order to evaluate this topic.

It is important to emphasize that at this time the lack of standardization of definition as well as standard criteria for diagnosing diabetic neuropathy are unsolved problems due to different worldwide consensus in the subject.

These consensuses have established scores like Neuropathy Symptoms Score NSS , Total Symptoms Score TSS , and Neuropathy Impairment Score NIS [ , , ] which addressed the intensity and frequency of the most important symptoms of diabetic neuropathy such as pain, burning, numbness and paresthesias.

The first of these studies was the ALADIN Alpha Lipoic Acid in Diabetic Neuropathy which was designed to evaluate the efficacy and safety of intravenous ALA during three weeks in three different doses, mg, mg and mg in comparison to placebo in patients with T2D with symptomatic distal symmetric diabetic polineuropathy DSPN [ ].

In this study an improvement in TSS was noted in the group using mg vs placebo establishing the safety and efficacy of this dose in comparison to the mg dose.

Moreover, at the dose of mg a higher rate of adverse events were observed mainly in the gastrointestinal tract. No difference in HbA1c was observed at the end of the study which included patients. This study was followed by ALADIN II which was a long-term trial 24 months that addressed also electrophysiological tests and Neuropathy Disability Score NDS using the same doses of ALA but orally in patients with T2D.

In this study only 65 patients could be included in the final analysis because the variability in the electrophysiological tests biased the final results [ ]. Although some improvement in sensory nerve function was noted the excessive number of patients excluded should be considered when interpreting these results.

The ALADIN III Study has combined mg of ALA intravenously for three weeks followed either by mg of ALA three times daily or placebo for six months 24 weeks [ ]. No improvement in TSS and NIS were observed at the end of the study, although some analyzed parameters such as NIS and TSS presented positive results in short period of ALA intravenously administration tree weeks.

Recently three randomized, double blind, controlled parallel studies were concluded addressing the efficacy and safety of ALA in diabetic patients with DSPN with TSS or NIS as primary outcome. The SYDNEY Trial, a monocenter, short-term study used ALA intravenously during five days a week for three weeks and showed improvement in TSS [ ].

The SIDNEY 2 Trial was a multicenter study which used doses of ALA ranging from to mg daily and also showed an improvement in TSS [ ]. In this study after a four-year treatment with ALA in mild-to-moderate DSPN did not influence the primary composite end point but resulted in a significant clinical improvement and prevention of progression of neuropathic impairments.

As the primary composite end point did not deteriorate in placebo-treated subjects, secondary prevention of its progression by ALA according to the trial design was not feasible [ ].

All these latter studies concluded that the usual dose of mg has efficacy and safety and adverse events, mainly in the gastrointestinal tract, that were dose dependent.

Moreover, with one exception sural latency , all these studies did observe improvement in electrophysiological tests. Two recent meta-analysis evaluate the use of ALA in diabetic neuropathy [ , ].

One, included 1, diabetic patients treated with mg of ALA, intravenously for three weeks, concluded that individualized TTS such as pain, numbness and burning decreased significantly with ALA in comparison to placebo. Considering the components of NIS-LL an improvement was noted in pin-prick, touch pressure and ankle reflexes [ ].

This meta-analysis also pointed out some relevant aspects for conducting future trials to evaluate the benefits of ALA on diabetic neuropathy as follows: homogeneity of the studied patients; duration of the trial; end-points with less variability and finally considering the slowing progression of diabetic neuropathy the end point must have to exclude the latter and address improvement.

Recently, a randomized, open label, parallel study showed no benefit of adding methylcobalamine ug and ALA mg to pregabalin 75 mg for 12 weeks in parameters of nerve function and pain evaluation [ ].

Another prospective, observational study showed that after 21 months patients using pregabalin had better improvement in symptoms of diabetic neuropathy in comparison to patients using either carbamazepine and ALA [ ]. Adverse events related to the administration of ALA were described mainly in clinical trials [ , , ] but generally without difference when compared with placebo.

The majority of these adverse events were dose-dependent and in the gastrointestinal tract nausea, vomiting, dyspepsia and abdominal pain. However other events were also described like pruritus, bronchitis and skin ulceration. Recently it was described a case of insulin autoimmune syndrome probably associated with the use of ALA as a nutritional supplement [ ].

ALA a natural anti-oxidant is a cofactor of mitochondrial enzymes of oxidative metabolism like pyruvate dehydrogenase which link glycolysis to citric acid cycle, and α-keto-glutarate dehydrogenase. ALA and its reduced form DHLA have many biological functions in different intracellular systems resulting in a wide range of actions such as antioxidant protection, chelation of metal ions, regeneration of other antioxidant agents such as vitamin C, E and glutathione.

To date, the majority of these actions have been addressed mainly in experimental studies which used a wide range dose of ALA in vitro as well as in vivo. We can also consider that for instance, the used dose was greater than the physiological dose reached with the usual clinically used oral dose of ALA.

It is also to be mentioned that in most of these studies it was not well defined which type of ALA has been used. Finally, the translation of all these pooled experimental data to human studies is a subject for further research.

Currently, there are compelling evidences linking oxidative damage to the majority of chronic diseases with increasing prevalence worldwide such as obesity, DM, CVD and AD. Considering the pleiotropic action of ALA upon different pathways associated with the above mentioned diseases, its use as a potential therapeutical agent seems promising.

So far, although in a limited number, the majority of clinical studies, performed in randomized double-blind and placebo-controlled ways, have been done in diabetic patients with DSPN.

Future clinical studies, also randomized double-blind and placebo-controlled with adequate sample calculation, homogeneity of the studied patients, longer duration and a minimal variability in the established outcomes are needed in order to asses the benefit of ALA upon other diabetes-related chronic complications.

Considering the latter statement it will be an important issue to define the use of ALA as primary or secondary therapeutic intervention. Also, the same aforementioned type of studies with the same criteria must be addressed in other clinical conditions such as obesity, CVD and AD.

Another important question to be answered by these clinical studies is when we are going to start its use according to the natural evolution of each disease in order to reach a benefit. We need also more experimental studies to evaluate and define if the pro-oxidant action of ALA is dose-dependent.

These studies may also give us more information about the use of lipoic acid synthase as a molecular target for increasing the mitochondrial levels of ALA. Another point to be addressed in these studies is the possibility that hyperglycemia can affect different pathways resulting in a toxicity which could be independent of oxidative stress as recently discussed [ ].

The role of endoplasmic reticulum stress has been pointed out as an important mechanism leading to diabetes-related complications which is independent of oxidative stress. Finally, although our review had the objective to extended our clinical and biological knowledge about ALA we still need more information about this multifunctional compound to spread its use in routine clinical practice.

Golbidi S, Badran M, Laher I: Diabetes and alpha lipoic Acid. Front Pharmacol. Article PubMed Central PubMed Google Scholar. Reed LJ: From lipoic acid to multi-enzyme complexes.

Protein Sci. Article PubMed Central CAS PubMed Google Scholar. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM: Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.

Biochim Biophys Acta. Snell EE, Strong FM, Peterson WH: Growth factor for bacteria. VI Fractionation and properties of an accessory factor for lactic acid bacteria. Bichem J. CAS Google Scholar. Reed LJ, De Busk BG, Gunsalus IC, Hornberger CS: Cristalline alpha-lipoic acid: a catalytic agent associated with pyruvate dehydrogenase.

Article CAS PubMed Google Scholar. Bock E, Schneeweiss J: Ein Beitrag zur Therapie der neuropathia diabetic. Munchner Med Wochenschrift. Google Scholar. McNeilly AM, Davison GW, Murphy MH, Nadeem N, Trinick T, Duly E, Novials A, McEneny J: Effect of α-lipoic acid and exercise training on cardiovascular disease risk in obesity with impaired glucose tolerance.

Lipids Health Dis. Ying Z, Kherada N, Farrar B, Kampfrath T, Chung Y, Simonetti O, Deiuliis J, Desikan R, Khan B, Villamena F, Sun Q, Parthasarathy S, Rajagopalan S: Lipoic acid effects on established atherosclerosis.

Life Sci. Ziegler D, Reljanovic M, Mehnert H, Gries FA: α Lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes. Packer L, Kraemer K, Rimbach G: Molecular aspects of lipoic acid in the prevention of diabetes complications.

Vasdev S, Ford CA, Parai S, Longerich L, Gadag V: Dietary alpha-lipoic acid supplementation lowers blood pressure in spontaneously hypertensive rats. J Hypertens. Moreira PI, Harris PLR, Zhu X, Santos MS, Oliveira CR, Smith MA, Perry G: Lipoic acidi and n-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts.

J Alzheimers Dis. CAS PubMed Google Scholar. Lott IT, Doran E, Nguyen VQ, Tournay A, Head E, Gillen DL: Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation. Am J Med Genet A.

Article PubMed Central PubMed CAS Google Scholar. Al Abdan M: Alfa-lipoic acid controls tumor growth and modulates hepatic redox state in Ehrlich-ascites-carcinoma-bearing mice. Scientific World Journal. Szelag M, Mikulski D, Molski M: Quantum-chemical investigation of the structure and the antioxidant properties of α-lipoic acid and its metabolites.

J Mol Model. Padmalayam I, Hasham S, Saxena U, Pillarisetti S: Lipoic acid synthase LASY : a novel role in inflammation, mitochondrial function, and insulin resistance.

McLain AL, Cormier PJ, Kinter M, Szweda LI: Glutathionylation of α-ketoglutarate dehydrogenase: the chemical nature and relative susceptibility of the cofactor lipoic acid to modification. Free Radic Biol Med. Article CAS Google Scholar.

Hassan BH, Cronan JE: Protein-protein interactions in assembly of lipoic acid on the 2-oxoacid dehydrogenases of aerobic metabolism. J Biol Chem.

Moini H, Tirosh O, Park YC, Cho KJ, Packer L: R-alpha-lipoic acid action on cell redox status, the insulin receptor, and glucose uptake in 3T3-L1 adipocytes. Arch Biochem Biophys.

A-Vadlapudi AD, Vadlapatla RK, Mitra AK: Sodium dependent multivitamin transporter SMVT : a potential target for drug delivery. Curr Drug Targets. Article Google Scholar.

A critical evaluation. Free Radic Res. Packer L, Witt EH, Tritschler HJ: Alpha-lipoic acid as a biological antioxidant. Free Rad Biol Med. Trujillo M, Radi R: Peroxynitrite reaction with the reduced and the oxidized forms of lipoic acid: new insights into the reaction of peroxynitrite with thiols.

Arch of Biochem and Biophys. Vriesman MF, Haenen GR, Westerveld GJ, Paquay JB, Voss HP, Bast A: A method for measuring nitric oxide radical scavenging activity. Scavenging properties of sulfur-containing compounds.

Pharm World Sci. Suzuki YJ, Tsuchiya M, Packer L: Thioctic acid and dihydrolipoic acid are novel antioxidants which interact with reactive oxygen species.

Free Radic Res Commun. Suzuki YJ, Tsuchiya M, Packer L: Antioxidant activities of dihydrolipoic acid and its structural homologues. Devasagayam TP, Di Mascio P, Kaiser S, Sies H: Singlet oxygen induced single-strand breaks in plasmid pBR DNA: the enhancing effect of thiols.

Kagan VE, Shvedova A, Serbinova E, Khan S, Swanson C, Powell R, Packer L: Dihydrolipoic acid—a universal antioxidant both in the membrane and in the aqueous phase.

Reduction of peroxyl, ascorbyl and chromanoxyl radicals. Biochem Pharmacol. Haenen GR, Bast A: Scavenging of hypochlorous acid by lipoic acid.

Newsholme P, Rebelato E, Abdulkader F, Krause M, Carpinelli A, Curi R: Reactive oxygen and nitrogen species generation, antioxidant defenses, and β-cell function: a critical role for amino acids. J Endocrinol. Brain Res. Wilking M, Ndiaye M, Mukhtar H, Ahmad N: Circadian rythms connections to oxidative stress: implications for human health.

Antioxid Redox Signal. Dicter N, Madar Z, Tirosh O: Alpha-lipoic acid inhibits glycogen synthesis in rat soleus muscle via its oxidative activity and the uncoupling of mitochondria. J Nutr. Rouchette L, Ghibu S, Richard C, Zeller M, Cottin Y, Vergely C: Direct and indirect antioxidant properties of α -lipoic acid.

Mol Nutr Food Res. Moini H, Packer L, Saris N-E: Antioxidant and prooxidant activities of α-lipoic acid and dihydrolipoic acid. Toxicol Appl Pharmacol. Zhang DD, Lo S-C, Cross JV, Templeton DJ, Hannink M: keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex.

Mol Cell Biol. Dinkova-kostova AT, Talalay P: Direct and indirect antioxidant properties of inducers of cytoprotective proteins.

PubMed Google Scholar. Frizzell N, Baynes JW: Chelation therapy: overlooked in the treatment and prevention of diabetes complications?.

Future Med Chem. Ou P, Tritscheler HJ, Wolff SP: Thioctic lipoic acid : a therapeutical metal-chelating antioxidant?. Bast A, Haenen GR: Lipoic acid: a multifunctional antioxidant.

Smith AR, Shenvi SV, Widlansky M, Suh JH, Hagen TM: Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem.

Yaworsky K, Somwar R, Ramlal T, Tritschler HJ, Klip A: Engagement of the insulin-sensitive pathway in the stimulation of glucose transport by alpha-lipoic acid in 3T3-L1 adipocytes.

Henriksen EJ, Jacob S, Streeper RS, Fogt DL, Hokama JY, Tritschler HJ: Stimulation by alpha-lipoic acid of glucose transport activity in skeletal muscle of lean and obese Zucker rats. Yamamoto Y, Gaynor RB: Therapeutical potential of inhibition of the NFkb pathway in the treatment of inflammation and cancer.

J Clin Invest. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M: Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med. Bierhaus A, Chevion S, Chevion M, Hofmann M, Quehenberger P, Illmer T, Luther T, Berentshtein E, Tritschler H, Müller M, Wahl P, Ziegler R, Nawroth PP: Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells.

Ying Z, Kampfrath T, Sun Q, Parthasarathy S, Rajagopalan S: Evidence that α-lipoic acid inhibits NF-κB activation independent of its antioxidant function.

Inflamm Res. Zembron-Lacny A, Gajeswski M, Naczac M, Dziewiecka H, Siatkkowski I: Physical activity and alpha-lipoic acid modulate inflammatory response through changes in thiol redox status. J Physiolo. Sola S, Mir MQ, Cheema FA, Khan-Merchant N, Menon RG, Parthasarathy S, Khan BV: Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction ISLAND study.

Steinberg GR, Kemp BE: AMPK in health and disease. Physiol Rev. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. Am J Physiol Cell Physiol.

Wang Y, Li X, Guo Y, Chan L, Guan X: Alpha-Lipoic acid increases energy expenditure by enhancing adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor-gamma coactivator-1alpha signaling in the skeletal muscle of aged mice.

Targonsky ED, Dai F, Koshkin V, Karaman GT, Gyulkhandanyan AV, Zhang Y, Chan CB, Wheeler MB: Alpha-lipoic acid regulates AMP-activated protein kinase and inhibits insulin secretion from beta cells.

Koh G, Yang EJ, Kim MK, Lee SA, Lee DH: Alpha-lipoic acid treatment reverses 2-deoxy-D-ribose-induced oxidative damage and suppression of insulin expression in pancreatic β-cells. Biol Pharm Bull. Ramamurthy S, Ronnet G: AMP-activated protein kinase AMPK and energy sensing in the brain.

Exp Neurobiol. Blazquez C, Geelen MJ, Velasco G, Guzmán M: The AMP activated protein kinase prevents ceramide synthesis de novo and astrocytes. FEBS Lett. Nakatsu Y, Kotake Y, Hino A, Ohta S: Activation of AMO-activated protein kinase by tributyltin induces neuronal cell death.

Kim MS, Park JY, Namkoong C, Jang PG, Ryu JW, Song HS, Yun JY, Namgoong IS, Ha J, Park IS, Lee IK, Viollet B, Youn JH, Lee HK, Lee KU: Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase.

Nat Med. Seo EY, Ha AW, Kim WK: α lipoic acid reduced weight gain and improved lipid profile in rats fed with high fat diet. Nutr Res Pract. Tomassoni D, Amenta F, Amantini C, Farfariello V, Di Cesare ML, Nwankwo IE, Marini C, Tayebati SK: Brain activity of thioctic acid enantiomers: in vitro and in vivo studies in an animal model of cerebrovascular injury.

Int J Mol Sci. Cho KJ, Moon HE, Moini H, Packer L, Yoon DY, Chung AS: Alpha-lipoic acid inhibits adipocyte differentiation by regulating pro-adipogenic transcription factors via mitogen-activated protein kinase pathways.

Wang Y, Dong W, Ding X, Wang F, Wang Y, Chen X, Yu L, Li X, Zhang A, Peng Y: Protective effect of α-lipoic acid on islet cells co-cultured with 3T3L1 adipocytes. Exp Ther Med. PubMed Central CAS PubMed Google Scholar. Tian YF, He CT, Chen YT, Hsieh PS: Lipoic acid suppresses portal endotoxemia-induced steatohepatitis and pancreatic inflammation in rats.

World J Gastroenterol. Ong SL, Vohra H, Zhang Y, Sutton M, Whitworth JA: The effect of alpha-lipoic acid on mitochondrial superoxide and glucocorticoid-induced hypertension. Oxid Med Cell Longev.

Epub Feb Li CJ, Lv L, Li H, Yu D: Cardiac fibrosis and dysfunctionin experimental diabetic cardiomyopathy are amelioreted by alpha-lipoic acid.

Cardiovasc Diabetol. PLoS One. Yi X, Nickeleit V, James LR, Maeda N: α-Lipoic acid protects diabetic apolipoprotein E-deficient mice from nephropathy. J Diabetes Complications. Inman DM, Lambert WS, Calkins DJ, Horner PJ: α-Lipoic acid antioxidant treatment limits glaucoma-related retinal ganglion cell death and dysfunction.

Jha MK, Jeon S, Suk K: Pyruvate Dehydrogenase Kinases in the nervous system: their principal functions in Neuronal-glial metabolic interaction and Neuro-metabolic disorders.

Curr Neuropharmacol. Expert Rev Neurother. J Nutr Health Aging. Adv Drug Deliv Rev. J Neural Transm Suppl. Int J Mol Med. Prieto-Hontoria PL, Pérez-Matute P, Fernández-Galilea M, Alfredo Martínez J, Moreno-Aliaga MJ: Effects of lipoic acid on AMPK and adiponectin in adipose tissue of low- and high-fat-fed rats.

Eur J Nutr. Deiuliis JA, Kampfrath T, Ying Z, Maiseyeu A, Rajagopalan S: Lipoic acid attenuates innate immune infiltration and activation in the visceral adipose tissue of obese insulin resistant mice.

Lamb RE, Goldstein BJ: Modulating an oxidative-inflmmatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function. Int J Clin Pract. Xiao C, Giacca A, Lewis GF: Short-term oral α-lipoic acid does not prevent lipid-induced dysregulation of glucose homeostasis in obese and overweight nondiabetic men.

Am J Physiol Endocrinol Metab. Zhang Y, Han P, Wu N, He B, Lu Y, Li S, Liu Y, Zhao S, Liu L, Li Y: Amelioration of lipid abnormalities by α-lipoic acid through antioxidative and anti-inflammatory effects. Obesity Silver Spring. Koh EH, Lee WJ, Lee SA, Kim EH, Cho EH, Jeong E, Kim DW, Kim MS, Park JY, Park KG, Lee HJ, Lee IK, Lim S, Jang HC, Lee KH, Lee KU: Effects of alpha-lipoic acid on body weight in obese subjects.

Am J Med. Ratliff JC, Palmese LB, Reutenauer EL, Tek C: An open-label pilot trial of alpha-lipoic acid for weight loss in patients with schizophrenia without diabetes. Clin Schizophr Relat Psychoses. Jose hotmail. Lean MEJ: Sibutramine: a review of clinical efficacy.

In J Obes. Lazo M, Clark JM: The epidemiology of nonalcoolic faty liver disease: a global perspective. Semin Liver Dis. Article PubMed Google Scholar. Valdecantos MP, Pérez-Matute P, González-Muniesa P, Prieto-Hontoria PL, Moreno-Aliaga MJ, Martínez JA: Lipoic acid administration prevents nonalcoholic steatosis linked to long-term high-fat feeding by modulating mitochondrial function.

J Nutr Biochem. Jung TS, Kim SK, Shin HJ, Jeon BT, Hahm JR, Roh GS: α-lipoic acid prevents non-alcoholic fatty liver disease in OLETF rats. Liver Int. Valdecantos MP, Pérez-Matute P, González-Muniesa P, Prieto-Hontoria PL, Moreno-Aliaga MJ, Martínez JA: Lipoic acid improves mitochondrial function in nonalcoholic steatosis through the stimulation of sirtuin 1 and sirtuin 3.

Chen WL, Kang CH, Wang SG, Lee HM: α-Lipoic acid regulates lipid metabolism through induction of sirtuin 1 SIRT1 and activation of AMP-activated protein kinase. Chong ZZ, Shang YC, Wang S, Maiesse K: SIRT1: new avenues of discovery for disorders of oxidative stress.

Expert Opin Ther Targets. Gurvits GE, Tan A: Burning mouth syndrome. Cavalcanti DR, da Silveira FR: Alpha lipoic acid in burning mouth syndrome—a randomized double-blind placebo-controlled trial.

J Oral Pathol Med. Femiano F, Lanza A, Buonaiuto C, Gombos F, Nunziata M, Cuccurullo L, Cirillo N: Burning mouth syndrome and burning mouth in hypothyroidism: proposal for a diagnostic and therapeutic protocol.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. Femiano F: Burning mouth syndrome BMS : an open trial of comparative efficacy of alpha-lipoic acid thioctic acid with other therapies.

Remember that you should not take supplements as a substitute for a varied balanced diet or healthy lifestyle. Alpha lipoic acid , commonly abbreviated as ALA , is an organic compound found in various foods and is also produced naturally in our bodies.

Renowned for its potent antioxidant properties, ALA has been the center of countless studies focusing on its potential health benefits. One of the most researched and highly regarded antioxidants available, alpha lipoic acid ALA , has piqued the interest of health enthusiasts worldwide.

Primarily touted for its impressive antioxidant properties, its potential extends to energy support, promoting healthy aging, and even assisting metabolism. One of the standout roles of ALA is its robust antioxidant capability. As the body progresses in age, its natural ability to produce ALA decreases.

Supplementing with Alpha Lipoic Acid helps replenish these levels, which can contribute to better cellular health, improved cognitive functions, and a sustained youthful appearance.

ALA is intricately linked to the cellular powerhouse - the mitochondria. Here, it plays a pivotal role in efficiently converting glucose into energy. This optimal energy conversion indirectly supports metabolic processes, making ALA an interesting topic for those keen on metabolic health.

ALA's antioxidant properties do wonders for the skin. Inflammation, when imbalanced, can affect the body's overall wellness. ALA , recognized for its inflammation balance attributes, assists in balancing and regulating the body's inflammatory response, ensuring cellular health and overall well-being.

While the common dosage for ALA in other brands is around mg for adults, our supplement stands apart by offering an extra punch. With mg of alpha lipoic acid , we ensure our consumers receive a more potent dosage, maximizing the benefits.

As time marches on, so does the natural aging process. However, with our best alpha lipoic acid supplement , you can combat the visible signs of aging. Our journey to optimal health is a continuous one, filled with choices at every turn.

By incorporating alpha lipoic acid into our wellness regimen, we are not just making a choice but a commitment.

A commitment to age gracefully, to support our energy and metabolism, and above all, to shield our body against the relentless onslaught of free radicals.

Sourced from the finest ingredients, our pure alpha lipoic acid stands out from the rest. We're proud to offer alpha lipoic acid mg capsules per serving that are free from fillers, binders, or any artificial components.

When you choose our lipoic acid supplement , you're choosing unparalleled quality. Alpha-lipoic acid ALA is a potent antioxidant found in supplements that supports several bodily functions.

Alpha-lipoic acid ALA supplements, including doses like mg of alpha-lipoic acid , are generally considered safe for most individuals when taken as directed.

For optimal alpha-lipoic acid benefits , it's typically recommended to take the supplement on an empty stomach, ideally 30 minutes before meals.

If you're considering a dose like mg of alpha-lipoic acid , consult with a healthcare professional to determine the best timing and dosage for your individual needs and to monitor for any potential interactions or side effects.

Alpha-lipoic acid is recognized for its antioxidant properties and potential benefits in various areas of health. If considering mg of alpha-lipoic acid or any dosage, it's essential to consult with a healthcare professional to evaluate its potential benefits and appropriateness for your specific needs.

Alpha-lipoic acid ALA is an antioxidant that can be beneficial for individuals looking to support their body's defense against oxidative stress. Alpha-lipoic acid ALA doesn't typically provide immediate results upon ingestion.

Like many supplements, its benefits may accrue over time with consistent use. The timeframe to notice any changes varies from person to person, based on factors like individual metabolism and the reason for supplementation. If considering mg of alpha-lipoic acid or other doses, it's always wise to consult with a healthcare provider about expectations and proper use.

Alpha-lipoic acid ALA has been studied for its potential role in supporting nerve health. Lipoic acid increased skeletal muscle mitochondrial biogenesis with increased phosphorylation of AMPK and messenger RNA expression of PGC-1alpha and glucose transporter Besides body fat mass, LA decreased lean mass and attenuated phosphorylation of mammalian target of rapamycin mTOR signaling in the skeletal muscle.

In cultured C2C12 cells, LA increased glucose uptake and palmitate beta-oxidation, but decreased protein synthesis, which was associated with increased phosphorylation of AMPK and expression of PGC-1alpha and glucose transporter-4, and attenuated phosphorylation of mTOR and p70S6 kinase.

We conclude that LA improves skeletal muscle energy metabolism in the aged mouse possibly through enhancing AMPK-PGC-1alpha-mediated mitochondrial biogenesis and function. Moreover, LA increases lean mass loss possibly by suppressing protein synthesis in the skeletal muscle by down-regulating the mTOR signaling pathway.

Abstract Skeletal muscle mitochondrial dysfunction is associated with aging and diabetes, which decreases respiratory capacity and increases reactive oxygen species.

Publication types Research Support, N.